New England Journal of Medicine October 01, 2026

Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes

Sean Wharton, Carel W le Roux, Elena Startseva, Isabel M Kloer, Ahmad Alhussein, Samina Ajaz Hussain, Anna Unseld, et al.

Source: View publication →

Bottom Line

In adults with obesity and type 2 diabetes, once-weekly treatment with the dual glucagon/GLP-1 receptor agonist survodutide resulted in significant weight loss and modest improvements in glycemic control compared to placebo, though gastrointestinal side effects were prevalent.

Key Findings

1. At week 76, the mean body weight change was -8.2% (95% CI, -9.2 to -7.2) with 3.6 mg survodutide, -9.8% (95% CI, -10.8 to -8.8) with 6.0 mg survodutide, and -3.9% (95% CI, -4.9 to -2.9) with placebo.

2. A clinically significant weight reduction of at least 5% was achieved by 57.6% of the 3.6-mg group, 64.5% of the 6.0-mg group, and 35.1% of the placebo group (P<0.001 for all comparisons vs. placebo).

3. Mean glycated hemoglobin (HbA1c) levels decreased from a baseline of 7.4% by 0.9 percentage points in the 3.6-mg group, 0.8 percentage points in the 6.0-mg group, and 0.2 percentage points in the placebo group.

4. Gastrointestinal adverse events were the most commonly reported side effects, occurring in 72.8% (182 participants) of the 3.6-mg group, 77.7% (195 participants) of the 6.0-mg group, and 38.6% (97 participants) of the placebo group.

Study Design

Design

RCT

Double-Blind

Sample

752

Patients

Duration

76 wk

Median

Setting

Multinational

Population Adults with type 2 diabetes and a body-mass index (BMI) of 27 or greater.

Intervention Once-weekly subcutaneous survodutide at a dose of 3.6 mg or 6.0 mg.

Comparator Once-weekly subcutaneous placebo.

Outcome Percent change in body weight and reduction in body weight of at least 5% from baseline to week 76.

Study Limitations

• High rates of gastrointestinal adverse events (affecting over 70% of survodutide recipients) suggest potential challenges with real-world tolerability, adherence, and early treatment discontinuation.

• The magnitude of weight loss observed in this type 2 diabetes cohort (-9.8% at the highest dose) was lower than historical efficacy seen in trials of patients with obesity without diabetes, though this blunted effect is typical for incretin-based therapies in diabetic populations.

• The 76-week trial duration limits the ability to assess very long-term safety, durability of weight maintenance post-treatment, or hard cardiovascular and microvascular outcome benefits, which are being investigated in separate trials.

Clinical Significance

Survodutide introduces a novel mechanism to the rapidly evolving landscape of anti-obesity medications by pairing glucagon receptor agonism (designed to increase energy expenditure and mobilize hepatic fat) with GLP-1 receptor agonism. For patients with co-occurring obesity and type 2 diabetes—a notoriously difficult population in which to achieve substantial weight reduction—survodutide demonstrates statistically significant efficacy. However, considering its highly prevalent gastrointestinal side effects and the robust benchmarks set by other incretin therapies like semaglutide and tirzepatide, meticulous dose titration and patient-centered discussions regarding tolerability will be essential in clinical practice.

Historical Context

The treatment paradigm for type 2 diabetes and obesity has been transformed in the 2020s by the advent of highly potent GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists, shifting the therapeutic focus aggressively toward weight management as a primary disease-modifying tool. Historically, glucagon agonism was avoided in diabetic patients due to concerns over exacerbating hyperglycemia by increasing hepatic glucose output. However, recent physiological insights demonstrated that combining glucagon agonism with GLP-1 agonism can counterbalance the hyperglycemic risks while capitalizing on glucagon's ability to drive energy expenditure. SYNCHRONIZE-2 serves as a pivotal phase 3 milestone validating that dual glucagon/GLP-1 agonism can effectively reduce body weight and improve HbA1c safely in a diabetic cohort.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

Why would a glucagon receptor agonist be included in a medication for Type 2 Diabetes, given that endogenous glucagon typically raises blood glucose?

Key Response

Glucagon increases energy expenditure, lipolysis, and satiety. When combined with a GLP-1 agonist, the GLP-1 component stimulates insulin secretion and counteracts the hyperglycemic effect of glucagon, allowing the patient to benefit from the enhanced weight loss and metabolic rate without worsening hyperglycemia.

Resident

Given the high prevalence of gastrointestinal side effects with survodutide, how would you counsel a patient initiating this medication, and what specific clinical strategies would you employ to maximize adherence?

Key Response

GI side effects like nausea and vomiting are major barriers to incretin-based therapies. Residents must know to implement slow dose titration, advise patients to eat smaller and lower-fat meals, ensure adequate hydration, and prescribe short-term anti-emetics if needed to prevent premature discontinuation of an effective therapy.

Fellow

How does the metabolic and catabolic profile of a GLP-1/Glucagon dual agonist like survodutide compare theoretically to a GLP-1/GIP dual agonist like tirzepatide regarding the preservation of lean body mass and hepatic lipid clearance?

Key Response

Glucagon agonism specifically targets hepatic lipid metabolism and increases resting energy expenditure, potentially offering superior benefits for concurrent MASLD. However, fellows must consider whether this increased catabolism carries a higher risk of lean muscle mass loss compared to the insulinotropic and anabolically protective effects of GIP seen in tirzepatide.

Attending

Considering survodutide yielded 'significant' weight loss but only 'modest' glycemic improvements, for which specific clinical phenotype of Type 2 Diabetes would you select this agent over highly efficacious dual GLP-1/GIP agents?

Key Response

Attendings must practice precision medicine. This agent might be uniquely suited for patients with severe obesity and prominent hepatic steatosis who already have relatively well-controlled HbA1c, rather than those with severe uncontrolled hyperglycemia who require agents with higher intrinsic glycemic efficacy.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

In assessing the glycemic efficacy of survodutide, what statistical methods or study designs are necessary to decouple the indirect HbA1c improvements driven by significant weight loss from the direct insulinotropic effects of the GLP-1 component?

Key Response

A robust mediation analysis is required to determine the proportion of HbA1c reduction attributable simply to losing significant body weight versus the direct pancreatic beta-cell effects. PhDs would scrutinize whether the trial included appropriate covariates to prove independent, direct glycemic efficacy.

Journal Editor

In an era where highly effective agents like semaglutide and tirzepatide are the standard of care for diabetes and obesity, does a placebo-controlled trial design still hold sufficient clinical relevance and ethical standing for a novel incretin therapy?

Key Response

A stringent peer reviewer would flag that a placebo comparator artificially inflates the perceived clinical magnitude of benefit. To have true editorial significance and real-world translational value, the drug should ideally be evaluated in a non-inferiority or superiority active-comparator trial against current guideline-directed medical therapies.

Guideline Committee

Current ADA guidelines stratify glucose-lowering agents by their weight loss and glycemic efficacies. Based on this trial, how should guidelines incorporate an agent with 'very high' weight loss but only 'modest' glycemic efficacy, and what level of evidence is required to update these algorithms?

Key Response

The ADA/EASD guidelines prioritize semaglutide and tirzepatide because they offer 'very high' efficacy in both weight and glycemic domains. The committee must decide if survodutide requires a new sub-pathway for obesity-predominant T2DM, and would likely demand head-to-head trials before recommending it as a first-line alternative to established dual or single agonists.

Clinical Landscape

Noteworthy Related Trials

2021

SURPASS-2

n = 1,879 · NEJM

Tested

Tirzepatide 5, 10, or 15 mg once weekly

Population

Adults with type 2 diabetes on metformin

Comparator

Semaglutide 1.0 mg once weekly

Endpoint

Change in HbA1c from baseline to 40 weeks

Key result: Tirzepatide was superior to semaglutide with respect to mean change in HbA1c and body weight.

2021

STEP 2

n = 1,210 · Lancet

Tested

Semaglutide 2.4 mg once weekly

Population

Adults with overweight or obesity and type 2 diabetes

Comparator

Semaglutide 1.0 mg or Placebo

Endpoint

Percentage change in body weight at week 68

Key result: Semaglutide 2.4 mg achieved superior and clinically meaningful weight loss compared to 1.0 mg and placebo.

2023

SURMOUNT-2

n = 938 · Lancet

Tested

Tirzepatide 10 mg or 15 mg once weekly

Population

Adults with obesity or overweight and type 2 diabetes

Comparator

Placebo

Endpoint

Percentage change in body weight at week 72

Key result: Tirzepatide led to substantial weight reduction of up to 14.7 percent, significantly greater than placebo.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis